Brief: Vincerx Pharma Presents Data On PTEFb/CDK9 Inhibitor VIP152 In DLBCL And CLL At 63rd American Society Of Hematology Annual Meeting
11/12/2021 20:35
Dec 11 (Reuters) - Vincerx Pharma Inc VINC.O :
* VINCERX PHARMA PRESENTS DATA ON PTEFB/CDK9 INHIBITOR
VIP152 IN
DLBCL AND CLL AT 63RD AMERICAN SOCIETY OF HEMATOLOGY ANNUAL
MEETING
* VINCERX PHARMA - VIP152 HAS INCREASED SELECTIVITY &
POTENCY
COMPARED TO OTHER CDK9 INHIBITORS IN DEVELOPMENT, CONSISTENT
ACROSS DLBCL & CLL MODELS OF DISEASE
Source text for Eikon: ID:nGNX1X5Mhp
Further company coverage: VINC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vincerx Pharma
See all newsBrief: Vincerx Pharma Announces Intent To Delist From Nasdaq And Deregister With The SEC
Brief: Vincerx Pharma Announces Termination Of Letter Of Intent And Board Authorization To Pursue Wind-Down Activities
Vincerx Pharma Inc reports results for the quarter ended December 31 - Earnings Summary
Vincerx Pharma Inc expected to post a loss of $3.40 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Aditxt, Natgas companies, DocuSign